ClinConnect ClinConnect Logo
Search / Trial NCT06890169

OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities

Launched by CHANGI GENERAL HOSPITAL · Mar 17, 2025

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Obesity Type 2 Diabetes Masld Nafld Telecare Telemedicine

ClinConnect Summary

The OneSTOP clinical trial is investigating a new way to help adults with obesity and related health issues, like type 2 diabetes and fatty liver disease, lose weight and improve their health. The trial compares a modern approach using telehealth—where patients can have video consultations with doctors and use an app called EMPOWER—to traditional in-person visits with doctors and dietitians. The goal is to see if the telehealth method is just as effective as regular visits for helping patients lose at least 5% of their weight, while also making it easier for them to track their diet and exercise.

To join the trial, participants need to be between 21 and 70 years old, have a body mass index (BMI) over 27.5, and have trouble controlling their diabetes or fatty liver disease. Throughout the 26-week program, participants will have a total of eight consultations—half in person and half through telehealth—and receive personalized advice on diet and exercise. They'll also learn to use the EMPOWER app to record their progress, which will help keep them on track. This study is currently recruiting, so if you or someone you know fits the criteria and is interested, it could be a valuable opportunity to improve health with the support of modern technology.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adults aged 21-70
  • Body mass index \> 27.5 kg/m2
  • Waist circumference \> 90 cm in men or 80 cm in women
  • Suboptimal control of type 2 diabetes (HbA1c \> 6.5%) AND/OR MASLD (as defined on radiological or histological evidence of hepatic steatosis in the absence of other chronic liver disease)
  • Exclusion Criteria:
  • Men who drink \> 21 units/week and women who drink \> 14 units/week of alcohol
  • Participants previously on weight-lowering medications (however if they are keen to participate, there will be a minimum wash-out period of 3 months before participation)
  • Illness with life expectancy of less than 6 months
  • Inability to comply with written instructions in English

About Changi General Hospital

Changi General Hospital (CGH) is a leading tertiary healthcare institution in Singapore, renowned for its commitment to providing high-quality patient care and advancing medical research. As a sponsor of clinical trials, CGH leverages its state-of-the-art facilities and multidisciplinary expertise to facilitate innovative research that aims to enhance treatment options and improve patient outcomes. The hospital is dedicated to upholding rigorous ethical standards and regulatory compliance while fostering collaboration with healthcare professionals and researchers to drive advancements in medical science. Through its clinical trials, CGH seeks to contribute to the global body of knowledge and translate research findings into practical applications for better healthcare delivery.

Locations

Singapore, , Singapore

Patients applied

0 patients applied

Trial Officials

Joan Khoo, MBBS, FRCP

Principal Investigator

Changi General Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported